AIT Therapeutics reports Q4 EPS (49c), consensus 28c
Reports Q4 revenue $7.7M, consensus $6.62M. "Our fiscal fourth quarter capped a year of significant accomplishments for AIT as we progress towards gaining regulatory approvals in the US and EU in the first half of 2020," said Steve Lisi, Chairman and Chief Executive Officer of AIT. "Along with our partner Circassia Pharmaceuticals, we anticipate a US launch of the AirNOvent* in the first half of 2020. Our programs in Bronchiolitis and NTM will both move forward in 2020 with data from two separate studies with the pivotal study for bronchiolitis anticipated to be completed in 2021 ." Mr. Lisi continued, "As we look forward, we consider ourselves very fortunate to have the opportunity to bring our nitric oxide generator and delivery system to patients around the world for, not just our first three indications, but for several others as well, such as pseudomonas aeruginosa lung infection and chronic obstructive pulmonary disease (COPD). I am confident that the team at AIT, soon to be the Beyond Air(TM) team, will continue to work tirelessly to help all patients who can benefit from NO therapy with our system."